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Abstract
Patients with inflammatory rheumatic diseases have an increased risk of cardiovascular disease, raising
questions of whether primary prevention strategies that are more aggressive than cardiac risk factor
modification alone should be implemented. Recent trials demonstrating the efficacy of statins in
reducing rates of cardiovascular events in healthy persons with elevated levels of C-reactive protein
broaden the potential protective mechanisms of statins, but do not directly translate to primary
cardiovascular disease prevention in patients with inflammatory rheumatic diseases.
Introduction and context
The risk of cardiovascular disease and cardiovascular
mortality is increased in patients with inflammatory
rheumatic diseases compared to the general population
or to persons without these diseases. Although an
increased risk is most well established for patients with
systemic lupus erythematosus and rheumatoid arthritis,
some evidence suggests an increased risk also exists for
patients with ankylosing spondylitis, psoriasis, and
psoriatic arthritis [1–5]. Although the reasons for this
increased risk are not completely understood, the
association between markers of inflammation, in parti-
cular, high-sensitivity C-reactive protein (hs-CRP), and
cardiovascular risk in patients without known inflam-
matory disease has led to speculation that systemic
inflammation itself may be etiologic [6–9]. Evidence that
cardiovascular events are reduced in patients who
respond to anti-inflammatory treatment supports this
view [10].
Recent advances
The JUPITER study (Justification for the Use of Statins in
Prevention: an Intervention Trial Evaluating Rosuvasta-
tin) tested whether treatment with rosuvastatin altered
the risk of incident cardiovascular events compared to
placebo in persons with a normal level of low-density
lipoprotein (LDL) cholesterol (less than 130 mg/ml) but
an elevated level of hs-CRP (2.0 mg/l or higher) [11].
Persons with systemic inflammatory diseases, including
severe arthritis and systemic lupus erythematosus, were
excluded, as were those being treated with prednisone
and other immunosuppressive medications. Subjects
(n = 17,802) were randomized to receive either 20 mg
rosuvastatin daily or placebo, for a planned duration of
5 years. The study's primary endpoint was the occurrence
of a first major cardiovascular event, including myocar-
dial infarction, stroke, hospitalization for unstable
angina or arterial revascularization, or death from a
cardiovascular cause.
The study was stopped prematurely when an interim
analysis found that cardiovascular events were signifi-
cantly less frequent in the group receiving rosuvastatin.
The primary endpoint was 44% less likely in the
rosuvastatin group than in the placebo group, although
the rates of events were low in both groups. Reduced
risks of similar magnitude were present for each
condition comprising the primary endpoint. There was
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rosuvastatin group. At 12 months, the median hs-CRP
level was 37% lower in the rosuvastatin group compared
to placebo, from a baseline level of 2.2 mg/l, and median
LDL cholesterol was 50% lower in the rosuvastatin group
compared to placebo, from a baseline level of 186 mg/dl.
These results indicate that treatment with rosuvastatin
can decrease cardiovascular events among patients with
an elevated hs-CRP level who do not have cholesterol
levels elevated to the threshold customarily used to begin
treatment. One possible implication of these results is
that primary prevention strategies should be broadened
to treat with statins those whose only cardiac risk factor is
an elevated hs-CRP level. But is this an appropriate
conclusion? Although subjects were selected based on
both an elevated hs-CRP level and a normal LDL
cholesterol level, the trial did not include a group with
low hs-CRP levels and, therefore, did not isolate the
benefit to patients with elevated hs-CRP levels specifi-
cally. Nor did it test hs-CRP as a screening tool to target
treatment, which would have required a parallel arm of
subjects who had not been tested for hs-CRP and were
treated without regard to hs-CRP level. In the strictest
interpretation, the JUPITER trial expands the potential
mechanisms by which statins reduce cardiovascular
events to include reductions in hs-CRP levels. Whether
this effect is completely independent of the hypocholer-
sterolemic effect is uncertain.
Implications for clinical practice
Given the elevated cardiovascular risk experienced by
patients with inflammatory rheumatic diseases, and the
association of elevated CRP levels with cardiovascular
disease, how should the results of the JUPITER trial be
applied to patients with inflammatory rheumatic dis-
eases? If hs-CRP levels in persons without inflammatory
diseases reflect inflammation in atherosclerotic endothe-
lial lesions, while hs-CRP (or CRP) levels in patients with
inflammatory diseases primarily reflect inflammation
outside the atherosclerotic endothelial lesions, elevated
hs-CRP levels would not be specific to the etiologic target
in patients with inflammatory diseases. In this case,
targeting treatment based on hs-CRP would not be
helpful, and treatment might not be expected to have the
same effects. Statins have multiple immunomodulatory
actions, which may have a role in their cardioprotective
effects [12]. Differences in activation or regulation of
these immune and inflammatory pathways between
patients with chronic inflammatory rheumatic diseases
and people without these diseases complicate using the
findings in non-rheumatic cohorts to predict effects in
rheumatic disease cohorts. Also to be considered is
whether any benefit of statins for primary prevention
would be attenuated or negated by anti-rheumatic
treatments, particularly chronic corticosteroids. Lastly,
the long-term safety of statins and unknown risks of
prolonged marked hypocholesterolemia would need to
be balanced against the potential benefits.
Given the difficulty applying the results of the JUPITER
trial to patients with inflammatory diseases, it would be
premature to recommend statins for primary prevention
of cardiovascular events in patients with inflammatory
rheumatic diseases. Rather, cardiac risk factor assessment
and modification should be enforced, while awaiting the
results of ongoing or recently completed studies speci-
fically investigating statins for primary cardiovascular
disease prevention in systemic lupus erythematosus and
rheumatoid arthritis [13–15].
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